Dynavax Technologies Corp (Dynavax) is a biopharmaceutical company that discovers and develops novel vaccines and therapeutics. It harnesses the power of the human body’s innate and adaptive immune responses through toll-like receptor stimulation. The company works on the modulation of endosomal TLRs, which are a family of transmembrane proteins that play a role in innate immunity and subsequent adaptive immunity. The company operates in one segment: discovery, commercialization, and development of novel vaccines.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Dynavax is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. These programs include vaccine candidates under development for shingles and plague, as well as additional vaccine programs in preclinical development. The company is also involved in partnerships to support the development of adjuvanted vaccines using CpG 1018 and has collaborated with organizations for COVID-19 vaccine development. The company is advancing a pipeline of investigational vaccine product candidates, including those for shingles and plague are in Phase I and Phase II trials. The R&D unit is responsible for the continued research and development of HEPLISAV-B and CpG 1018 adjuvant, clinical product candidates, and preclinical studies. This includes managing costs incurred under agreements with contract research organizations, contract manufacturing organizations, and service providers that assist in conducting clinical studies, as well as costs associated with preclinical activities and regulatory operations. The company has major technology alliances with organizations such as Valneva Austria GmbH, Medigen Vaccine Biologics Corporation, and Colorado State University Research Foundation. In FY2024, the company spent US$61.6 million on R&D, which, as a percentage of revenue, stood at 2.2% and grew 12.1% YoY. As of December 2024, Dynavax's intellectual property portfolio included over 20 issued US patents, over 45 granted foreign patents, and over 130 additional pending US non-provisional and foreign patent applications.